Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin with SBRT in NSCLC
NCT02285855Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2015
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of liquid metformin (Aspargo Labs) in non-small cell lung cancer (NSCLC) (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: RECIST and PERCIST Tumor Response at 6 months. Started Feb 2015; status: terminated.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02285855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02285855.